Kathryn A. Gold, MD Appointed Chief of the Division of Hematology and Oncology at Moores Cancer Center |
Dr. Kate Gold has been appointed Chief of the Division of Hematology and Oncology at Moores, effective November 1, 2023. Dr. Gold was selected as interim Chief for the division, after an internal search earlier this year.
|
J. Silvio Gutkind, PhD Named American Cancer Society Research Professor
|
The nation’s largest non-government, non-profit funder of cancer researcher, American Cancer Society (ACS), has awarded Moores Member, J. Silvio Gutkind, PhD with the ACS Research Professor Award. Professor Gutkind is one of two recipients to receive this highly prestigious award for investigators who have made ground-breaking contributions in cancer research.
|
Moores Cancer Center 2023 Annual Retreat Recap |
Moores held another wonderful scientific retreat by the ocean, a testament to the camaraderie, collaboration, and coordination germane to delivering the discoveries of Moores researchers and clinicians to the patients and communities of San Diego. Retreat organizers extend their immense gratitude to all involved, including keynote speakers, award recipients, participants, staff, and volunteers, for contributing to the huge success of the event. See you again in 2024!
|
Jawsome Shark Tank Winners
|
- Hannah Carter, PhD, PI
- Sandip Patel, MD, PI
- Theresa Guo, MD, Co-I
- Maurizio Zanetti, MD, Co-I
|
- Jerry DeWitt, Svasti Haricharan Lab, SDSU and Megha Raghunathan, Svasti Haricharan Lab, SDSU (Cancer Control Program)
-
Clara Hu, Trey Ideker Lab (Structural and Functional Genomics)
- Jaya Lakhshmi, Dan Kaufman Lab (Hematologic Malignancies)
- Magalie Dosset, Maurizio Zanetti Lab (Solid Tumor Therapeutics)
- Mengdan Liu, Dong-Er Zhang Lab and Mika Caplan, JoAnn Trejo Lab (Cancer Biology and Signaling)
|
UBE4B Interacts with the ITCH E3 Ubiquitin Ligase to Induce Ku70 and c-FLIPL Polyubiquitination and Enhanced Neuroblastoma Apoptosis |
Although expression of the UBE4B ubiquitin ligase is strongly associated with neuroblastoma patient outcomes, the functional roles of UBE4B in neuroblastoma pathogenesis are unknown. Moores Member Peter Zage, MD, PhD has identified novel targets for UBE4B activity and a direct role for UBE4B in responses of neuroblastoma cells to histone deacetylase inhibition, which suggests not only the critical role that UBE4B plays in responses of neuroblastoma tumors to therapy, but also a potential new and improved strategy for treatment of children with neuroblastoma.
|
|
|
The Science Of . . . Live Podcast Recording |
November 30, 2023 | 4:00 p.m. to 6:00 p.m.
Moores Comer Commons
|
November 27, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
November 28, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building
|
November 29, 2023 | 10:00 a.m.
NSB 1205 Auditorium
|
|
|
MD Anderson Cancer Center Grant Spotlight Series |
December 1, 2023 | 1:00 p.m. to 2:30 p.m. CST
|
Join Clifton (Dave) Fuller, MD, PhD, Guan-Yu Xiao, PhD, and Ivan H.C. Wu, PhD to learn about the K99/R00 mechanism and what reviewers look for in a successful application. Please contact Heather Brien (HMBrien@mdanderson.org) for more information. View Flyer for More Details
|
NCI Intramural Continuing Umbrella of Research Experiences (iCURE) |
iCURE brings cohorts of students and scientists from diverse backgrounds into the multidisciplinary environment of NCI and supports their mentored research experiences. The program provides 2-year awards for post-baccalaureate and graduate students and 3-year awards for postdoctoral fellows. Applications will be accepted through December 6, 2023. Learn More and Apply
|
|
|
FEATURED FUNDING OPPORTUNITIES |
2023 Moores Pre-Award and Grant Development Services, Processes, and Timelines
|
Learn about the Pre-Award Research Administration Team (PRA), the Grant Development Team (GDT), and how and when to access the Moores Proposal Intake Form
|
Pre-Award Services and How to Access Them—the following services are provided for faculty/grants in the Moores space: |
- Uploading proposal documents to internal and external submission systems
- Providing review of the application for completion
- Preparing budgets and budget justifications
- Facilitating adherence to checklists and timelines
- Placing the proposal in the submission queue
- Serving as liaison between PI and OCGA/HSSPPO
- Assistance with JIT (just-In-time) requests
|
Grant Development Services and How to Access Them—these services are provided for all Moores Members, based on priority: |
- Reserving or requesting services
- Identifying funding opportunities
-
Providing templates and examples
- Providing scientific review and/or meticulous editing
- Crafting supporting documents (e.g., Letters of Support, Facilities, et al.), biosketch formatting/editing, and wording sections for lay audiences
|
|
|
| Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: Externally controlled, propensity score-matched survival outcome comparisons |
Journal of Clinical Oncology
|
William D. Roberts, MD (Hematologic Malignancies) and Peter E. Zage, MD, PhD (Structural and Functional Genomics)
|
|
|
| Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis |
Claude B. Sirlin, MD (Solid Tumor Therapeutics), Kathryn Fowler, MD (Solid Tumor Therapeutics), Rohit Loomba, MD (Cancer Control Program)
|
|
|
| Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial |
Caitlin L. Costello, MD (Hematologic Malignancies)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
GPC-100-001: A Phase II, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol with and without GCSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant |
PI: Ah-Reum (Autumn) Jeong, MD
NCT: NCT05561751
|
Ph1 INBRX-109: An Open-Label, Multicenter, First-in-Human, Phase I Dose-Escalation and Multicohort Expansion Study of INBRX109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas |
PI: Adam Burgoyne, MD, PhD
NCT: NCT03715933
|
TRANSFORMATION INITIATIVE |
Week of November 20, 2023 |
-
Fifty-five trials have entered Fast Lane, 16 of which have been activated to date across the Lung, Breast, GU, Gyn, H&N, BMT, Skin and ET disease teams. Many thanks to the cross-functional teams across UC San Diego for their outstanding efforts to prioritize these high-priority trials for Moores patients.
-
As CTO nears “Go-Live,” training materials for Start-Up and Disease Team PMs on new processes are being developed. Please watch for upcoming training sessions to be scheduled. Many thanks to the Business and Finance Process workstream members for their continued support of these exciting initiatives.
-
The next CTO Town Hall will take place on Tuesday, November 28, 2023 from 9:00 a.m. to 10:15 a.m. CTO looks forward to sharing more exciting updates.
- Keep the feedback coming! You are encouraged to continue working with your managers and sharing your feedback to inform future communications and upcoming Town Hall topics.
|
|
|
EQUITY, DIVERSITY, AND INCLUSION (EDI) |
November is Native American Heritage Month |
Moores is proud to celebrate its unique culture by recognizing November as Native American Heritage Month, in alignment with a draft statement by the UCSD Intertribal Resource Center:
The UC San Diego community holds great respect for the land and the original people of the area where our campus is located. The university is built on the un-ceded territory of the Kumeyaay Nation. Today, the Kumeyaay people continue to maintain their political sovereignty and cultural traditions as vital members of the San Diego community. We acknowledge their tremendous contributions to our region and thank them for their stewardship.
The Intertribal Resource Center is working with Kumeyaay community members and the campus community to create an official statement for UC San Diego. Please visit https://itrc.ucsd.edu/ for more information and resources to help Moores celebrate you.
Moores Members are encouraged to contact EDI to recognize Native staff, researchers, faculty, or trainees (students) who have contributed to the community. Please share your nominees' names, email, and two to three sentences about their contribution to Moores, patient care, and/or research at mcc_edi@health.ucsd.edu.
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
The Science Of . . . Emergency Medicine |
Episode 8 of The Science Of . . . podcast is now available! In this episode, our student hosts discuss the science of emergency medicine with Dr. Faith Quenzer, an Emergency Medicine Physician and Researcher who has worked in both the public health setting and the healthcare industry.
Listen Now on Spotify
|
COE at Assemblymember Akilah Weber's Annual Turkey Giveaway |
Over the past weekend, COE participated in Assemblymember Akilah Weber's annual turkey giveaway and engaged more than 90 participants, providing valuable cancer prevention resources and education, as part of lung cancer awareness month.
|
COE at Cervivor's Expert Hour Workshop |
COE's Margaux Stack-Babich joined Cervivor's expert hour workshop on Thursday, November 16, 2023 and led a talk on the importance of working together to reduce the burden of—and ultimately put an end to—cervical cancer.
|
|
|
|
